ABVC BioPharma (NASDAQ:ABVC) Issues Quarterly Earnings Results

ABVC BioPharma (NASDAQ:ABVC - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share for the quarter, Zacks reports. ABVC BioPharma had a negative return on equity of 29.62% and a negative net margin of 963.46%.Get ABVC BioPharma alerts:ABVC BioPharma Trading Up 1.0%Shares of ABVC BioPharma stock traded up $0.03 during mid-day trading on Wednesday, reaching $2.97. 77,893 shares of the stock were exchanged, compared to its average volume of 482,299. The company has a market cap of $50.44 million, a price-to-earnings ratio of -22.85 and a beta of 0.27. The firm has a 50-day simple moving average of $2.72 and a 200 day simple moving average of $1.52. ABVC BioPharma has a fifty-two week low of $0.40 and a fifty-two week high of $5.48. Institutional Investors Weigh In On ABVC BioPharmaAn institutional investor recently raised its position in ABVC BioPharma stock. Geode Capital Management LLC increased its position in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC - Free Report) by 5.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 110,499 shares of the company's stock after acquiring an additional 6,017 shares during the quarter. Geode Capital Management LLC owned about 0.65% of ABVC BioPharma worth $246,000 as of its most recent SEC filing. 11.38% of the stock is owned by institutional investors and hedge funds. About ABVC BioPharma (Get Free Report)ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.Further ReadingFive stocks we like better than ABVC BioPharmaPets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your PortfolioAmazon’s Bears Have Raised the White Flag—Get ExcitedWhat is Short Interest? How to Use ItTempus AI’s Strong Q2 Fuels Growth Story—More Upside Ahead?Special Purpose Acquisition Company (SPAC) What You Need to Know CAVA’s Honeymoon Ends With a 16% Stock DropThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in ABVC BioPharma Right Now?Before you consider ABVC BioPharma, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABVC BioPharma wasn't on the list.While ABVC BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here